How to address residual risk post ACS: LDL-c, Dyslipdemia, and Inflammation

Episodes 1-3 of 3

• 

  RestartResume

  Beyond statins: The role of ezetimibe in targeting residual risk

  RestartResume

  Beyond statins: The role of ezetimibe in targeting residual risk

  ESC 2016

  Beyond statins: The role of ezetimibe in targeting residual risk

  • 

    

    Chris Packard, MD

• 

  RestartResume

  Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

  RestartResume

  Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

  ESC 2016

  Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

  • 

    

    Erik Stroes, MD

• 

  RestartResume

  Inflammation as potential target for therapy to target residual risk post ACS

  RestartResume

  Inflammation as potential target for therapy to target residual risk post ACS

  ESC 2016

  Inflammation as potential target for therapy to target residual risk post ACS

  • 

    

    Paul M Ridker, MD